Is there hard evidence that spironolactone could help treat COVID-19?
Friday, January 29, 2021
By Stevie Rosignol-Cortez
Copy link
Copy featured image
NO
Spironolactone, given what‘s known about its effects on the body, has been considered as a possible candidate to treat at least some conditions associated with COVID-19. But the drug is untested in clinical trials.
Spironolactone is anti-inflammatory and anti-fibrotic, potentially making it useful against pulmonary complications of COVID-19 such as pulmonary fibrosis. Preliminary theories posit that the drug could mitigate risk factors like hypertension and androgen exposure and provide protection from the virus.
This fact brief is responsive to conversations such as this one.
Sources
ABOUT THE CONTRIBUTOR
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.
FACT BRIEF BY
